DOCSLIB.ORG

Ambetter 90-Day-Maintenance Drug List- 2020

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Ambetter 90-Day-Maintenance Drug List- 2020 Ambetter 90-Day-Maintenance Drug List Guide to this list: What is Ambetter 90‐Day‐Maintenance Drug List? Ambetter 90‐Day‐Supply Maintenance Drug List is a list of maintenance medications that are available for 90 day supply through mail order or through our Extended Day Supply Network. How do I find a pharmacy that is participating in Extended Day Supply Network? To find a retail pharmacy that is participating in our Extended Day Supply Network please consult information available under Pharmacy Resources tab on our webpage. Alternatively, you can utilize our mail order pharmacy. Information on mail order pharmacy is available in Pharmacy Resources tab on our webpage. Are all formulary drugs covered for 90 day supply? No, certain specialty and non‐specialty drugs are excluded from 90 day supply. Please consult 90‐Day‐ Supply Maintenance Drug List for information if your drug is included. A Amlodipine Besylate-Atorvastatin Calcium Acamprosate Calcium Amlodipine Besylate-Benazepril HCl Acarbose Amlodipine Besylate-Olmesartan Medoxomil Acebutolol HCl Amlodipine Besylate-Valsartan Acetazolamide Amlodipine-Valsartan-Hydrochlorothiazide Albuterol Sulfate Amoxapine Alendronate Sodium Amphetamine-Dextroamphetamine Alendronate Sodium-Cholecalciferol Anagrelide HCl Alfuzosin HCl Anastrozole Aliskiren Fumarate Apixaban Allopurinol Arformoterol Tartrate Alogliptin Benzoate Aripiprazole Alosetron HCl Armodafinil Amantadine HCl Asenapine Maleate Amiloride & Hydrochlorothiazide Aspirin-Dipyridamole Amiloride HCl Atenolol Amiodarone HCl Atenolol & Chlorthalidone Amitriptyline HCl Atomoxetine HCl Amlodipine Besylate Atorvastatin Calcium Inclusion of drugs on this list does not guarantee coverage. Please consult your benefit materials for further information. © 2020 Arizona Complete Health, which is underwritten by Health Net of Arizona, Inc. All rights reserved. 1-866-918-4450 (TTY: 711) 1870 W Rio Salado Suite 2A Tempe, AZ 85281 Ambetter.AZcompletehealth.com Auranofin Chlorothiazide Azathioprine Chlorpromazine HCl Azilsartan Medoxomil Chlorpropamide Chlorthalidone B Cholestyramine Beclomethasone Dipropionate HFA Cholestyramine Light Benazepril & Hydrochlorothiazide Cilostazol Benazepril HCl Cimetidine Benztropine Mesylate Cimetidine HCl Betaxolol HCl Citalopram Hydrobromide Betaxolol HCl (Ophth) Clobazam Betrixaban Maleate Clomipramine HCl Bimatoprost Clonidine Bisoprolol & Hydrochlorothiazide Clonidine HCl Bisoprolol Fumarate Clonidine HCl (ADHD) Brexpiprazole Clopidogrel Bisulfate Brimonidine Tartrate Colchicine w/ Probenecid Brimonidine Tartrate-Timolol Maleate Colesevelam HCl Brinzolamide-Brimonidine Tartrate Colestipol HCl Brivaracetam Conjugated Estrogens-Bazedoxifene Bromocriptine Mesylate Conjugated Estrogens-Medroxyprogesterone Bromocriptine Mesylate (Diabetes) Acetate Budesonide (Inhalation) Cromolyn Sodium Budesonide-Formoterol Fumarate Dihydrate Cyclosporine Bumetanide Cyclosporine (Ophth) Bupropion HCl Cyclosporine Modified (For Microemulsion) Cysteamine Bitartrate C Cysteamine HCl Calcitonin (Salmon) Calcitriol D Calcium Acetate (Phosphate Binder) Dapagliflozin Propanediol Candesartan Cilexetil Dapagliflozin-Metformin HCl Candesartan Cilexetil-Hydrochlorothiazide Dapsone Cannabidiol Darifenacin Hydrobromide Captopril Deferiprone Carbamazepine Desipramine HCl Carbamazepine (Antipsychotic) Desmopressin Acetate Carbidopa Desmopressin Acetate Spray Carbidopa-Levodopa Desmopressin Acetate Spray Refrigerated Carbidopa-Levodopa-Entacapone Desogestrel & Ethinyl Estradiol Carteolol HCl (Ophth) Desogestrel-Ethinyl Estradiol (Biphasic) Carvedilol Desogestrel-Ethinyl Estradiol (Triphasic) Celecoxib Desvenlafaxine Succinate Cevimeline HCl Dexlansoprazole Chloroquine Phosphate Dexmethylphenidate HCl Inclusion of drugs on this list does not guarantee coverage. Please consult your benefit materials for further information. © 2020 Arizona Complete Health, which is underwritten by Health Net of Arizona, Inc. All rights reserved. 1-866-918-4450 (TTY: 711) 1870 W Rio Salado Suite 2A Tempe, AZ 85281 Ambetter.AZcompletehealth.com Dextroamphetamine Sulfate Escitalopram Oxalate Dextromethorphan HBr-Quinidine Sulfate Eslicarbazepine Acetate Diazoxide Esomeprazole Magnesium Diclofenac Potassium Esterified Estrogens Diclofenac Sodium Estradiol Diclofenac w/ Misoprostol Estradiol Acetate Vaginal Diflunisal Estradiol Vaginal Digoxin Estradiol Valerate-Dienogest Diltiazem HCl Estradiol-Levonorgestrel Diltiazem HCl Coated Beads Estrogens, Conjugated Diltiazem HCl Extended Release Beads Estrogens, Conjugated Vaginal Dipyridamole Ethacrynic Acid Disopyramide Phosphate Ethosuximide Disulfiram Ethotoin Divalproex Sodium Ethynodiol Diacet & Eth Estrad Dofetilide Etodolac Donepezil Hydrochloride Etonogestrel-Ethinyl Estradiol Dorzolamide HCl Ezetimibe Dorzolamide HCl-Timolol Maleate Ezetimibe-Simvastatin Doxazosin Mesylate Doxepin HCl F Doxercalciferol Famotidine Dronedarone HCl Febuxostat Drospirenone Felbamate Drospirenone-Ethinyl Estradiol Felodipine Drospirenone-Ethinyl Estradiol-Levomefolate Fenofibrate Calcium Fenofibrate Micronized Dulaglutide Fenoprofen Calcium Duloxetine HCl Fesoterodine Fumarate Dutasteride Finasteride Flavoxate HCl E Flecainide Acetate Echothiophate Iodide Fludrocortisone Acetate Empagliflozin Fluoxetine HCl Empagliflozin-Metformin HCl Fluoxetine HCl (PMDD) Enalapril Maleate Fluphenazine HCl Enalapril Maleate & Hydrochlorothiazide Flurbiprofen Entacapone Fluticasone Furoate (Inhalation) Eplerenone Fluticasone Furoate-Vilanterol Eprosartan Mesylate Fluticasone Propionate (Inhalation) Erenumab-aooe Fluticasone Propionate HFA Ergocalciferol Fluticasone-Salmeterol Ergoloid Mesylates Fluticasone-Umeclidinium-Vilanterol Ertugliflozin L-Pyroglutamic Acid Fluvastatin Sodium Ertugliflozin-Metformin HCl Fluvoxamine Maleate Inclusion of drugs on this list does not guarantee coverage. Please consult your benefit materials for further information. © 2020 Arizona Complete Health, which is underwritten by Health Net of Arizona, Inc. All rights reserved. 1-866-918-4450 (TTY: 711) 1870 W Rio Salado Suite 2A Tempe, AZ 85281 Ambetter.AZcompletehealth.com Folic Acid Insulin Detemir Fosinopril Sodium Insulin Glargine Fosinopril Sodium & Hydrochlorothiazide Insulin NPH (Human) (Isophane) Furosemide Insulin NPH Isophane & Reg (Human) Insulin Regular (Human) G Ipratropium Bromide Gabapentin Ipratropium Bromide (Nasal) Gabapentin Enacarbil Ipratropium Bromide HFA Galantamine Hydrobromide Ipratropium-Albuterol Galcanezumab-gnlm Irbesartan Gemfibrozil Irbesartan-Hydrochlorothiazide Glatiramer Acetate Isocarboxazid Glimepiride Isoniazid Glipizide Isosorbide Dinitrate Glipizide-Metformin HCl Isosorbide Dinitrate-Hydralazine HCl Glyburide Isosorbide Mononitrate Glyburide Micronized Isradipine Glyburide-Metformin Ivabradine HCl Glycopyrrolate-Formoterol Fumarate Guanfacine HCl K Guanfacine HCl (ADHD) Ketoprofen H L Haloperidol Labetalol HCl Haloperidol Lactate Lacosamide Hydralazine HCl Lactulose Hydrochlorothiazide Lactulose (Encephalopathy) Hydroxychloroquine Sulfate Lamivudine (HBV) Hydroxyurea (Sickle Cell Anemia) Lamotrigine Lansoprazole I Lanthanum Carbonate Ibandronate Sodium Latanoprost Ibuprofen Leflunomide Icosapent Ethyl Lesinurad Imipramine HCl Lesinurad-Allopurinol Imipramine Pamoate Letrozole Indacaterol Maleate Levalbuterol HCl Indacaterol Maleate-Glycopyrrolate Levalbuterol Tartrate Indapamide Levetiracetam Indomethacin Levobunolol HCl Insulin Aspart Levomilnacipran HCl Insulin Aspart (with Niacinamide) Levonorgestrel & Eth Estradiol Insulin Aspart Protamine & Aspart (Human) Levonorgestrel-Eth Estradiol (Triphasic) Insulin Degludec Levonorgestrel-Ethinyl Estradiol & Folic Acid Insulin Degludec-Liraglutide Levonorgestrel-Ethinyl Estradiol (91-Day) Inclusion of drugs on this list does not guarantee coverage. Please consult your benefit materials for further information. © 2020 Arizona Complete Health, which is underwritten by Health Net of Arizona, Inc. All rights reserved. 1-866-918-4450 (TTY: 711) 1870 W Rio Salado Suite 2A Tempe, AZ 85281 Ambetter.AZcompletehealth.com Levonorgestrel-Ethinyl Estradiol (Continuous) Mexiletine HCl Levonorgestrel-Ethinyl Estradiol-Ferrous Miglitol Bisglycinate Milnacipran HCl Levothyroxine Sodium Minoxidil Linaclotide Mirabegron Liothyronine Sodium Mirtazapine Liraglutide Misoprostol Lisdexamfetamine Dimesylate Modafinil Lisinopril Moexipril HCl Lisinopril & Hydrochlorothiazide Montelukast Sodium Lithium Mycophenolate Mofetil Lithium Carbonate Mycophenolate Sodium Losartan Potassium Losartan Potassium & Hydrochlorothiazide N Lovastatin Nabumetone Loxapine Succinate Nadolol Lubiprostone Naproxen Lurasidone HCl Naproxen Sodium Nateglinide M Nebivolol HCl Maprotiline HCl Nefazodone HCl Mecamylamine HCl Niacin (Antihyperlipidemic) Meclofenamate Sodium Niacin-Lovastatin Medroxyprogesterone Acetate Niacin-Simvastatin Mefenamic Acid Nicardipine HCl Mefloquine HCl Nifedipine Megestrol Acetate (Appetite) Nisoldipine Meloxicam Nitroglycerin Memantine HCl Nizatidine Mesalamine Norelgestromin-Ethinyl Estradiol Metaproterenol Sulfate Norethin Acet & Estrad-Fe Metformin HCl Norethindrone & Eth Estradiol Methamphetamine HCl Norethindrone & Ethinyl Estradiol-Fe Methazolamide Norethindrone (Contraceptive) Methimazole Norethindrone Acet & Eth Estra Methsuximide Norethindrone Acetate Methyclothiazide Norethindrone Acetate-Ethinyl Estradiol Methyldopa Norethindrone Acetate-Ethinyl Estradiol-Fe Methylphenidate Norethindrone Acetate-Ethinyl Estradiol-Fe Fum Methylphenidate HCl (Biphasic) Methyltestosterone Norethindrone-Eth Estradiol
Load more

Recommended publications
  • SPIRONOLACTONE Spironolactone – Oral (Common Brand Name
    SPIRONOLACTONE Spironolactone – oral (common brand name: Aldactone) Uses: Spironolactone is used to treat high blood pressure. Lowering high blood pressure helps prevent strokes, heart attacks, and kidney problems. It is also used to treat swelling (edema) caused by certain conditions (e.g., congestive heart failure) by removing excess fluid and improving symptoms such as breathing problems. This medication is also used to treat low potassium levels and conditions in which the body is making too much of a natural chemical (aldosterone). Spironolactone is known as a “water pill” (potassium-sparing diuretic). Other uses: This medication has also been used to treat acne in women, female pattern hair loss, and excessive hair growth (hirsutism), especially in women with polycystic ovary disease. Side effects: Drowsiness, lightheadedness, stomach upset, diarrhea, nausea, vomiting, or headache may occur. To minimize lightheadedness, get up slowly when rising from a seated or lying position. If any of these effects persist or worsen, notify your doctor promptly. Tell your doctor immediately if any of these unlikely but serious side effects occur; dizziness, increased thirst, change in the amount of urine, mental/mood chances, unusual fatigue/weakness, muscle spasms, menstrual period changes, sexual function problems. This medication may lead to high levels of potassium, especially in patients with kidney problems. If not treated, very high potassium levels can be fatal. Tell your doctor immediately if you notice any of the following unlikely but serious side effects: slow/irregular heartbeat, muscle weakness. Precautions: Before taking spironolactone, tell your doctor or pharmacist if you are allergic to it; or if you have any other allergies.
    [Show full text]
  • Table 2. 2012 AGS Beers Criteria for Potentially
    Table 2. 2012 AGS Beers Criteria for Potentially Inappropriate Medication Use in Older Adults Strength of Organ System/ Recommendat Quality of Recomm Therapeutic Category/Drug(s) Rationale ion Evidence endation References Anticholinergics (excludes TCAs) First-generation antihistamines Highly anticholinergic; Avoid Hydroxyzin Strong Agostini 2001 (as single agent or as part of clearance reduced with e and Boustani 2007 combination products) advanced age, and promethazi Guaiana 2010 Brompheniramine tolerance develops ne: high; Han 2001 Carbinoxamine when used as hypnotic; All others: Rudolph 2008 Chlorpheniramine increased risk of moderate Clemastine confusion, dry mouth, Cyproheptadine constipation, and other Dexbrompheniramine anticholinergic Dexchlorpheniramine effects/toxicity. Diphenhydramine (oral) Doxylamine Use of diphenhydramine in Hydroxyzine special situations such Promethazine as acute treatment of Triprolidine severe allergic reaction may be appropriate. Antiparkinson agents Not recommended for Avoid Moderate Strong Rudolph 2008 Benztropine (oral) prevention of Trihexyphenidyl extrapyramidal symptoms with antipsychotics; more effective agents available for treatment of Parkinson disease. Antispasmodics Highly anticholinergic, Avoid Moderate Strong Lechevallier- Belladonna alkaloids uncertain except in Michel 2005 Clidinium-chlordiazepoxide effectiveness. short-term Rudolph 2008 Dicyclomine palliative Hyoscyamine care to Propantheline decrease Scopolamine oral secretions. Antithrombotics Dipyridamole, oral short-acting* May
    [Show full text]
  • Sodium Phenylbutyrate (PB), Is a New Active Substance
    SCIENTIFIC DISCUSSION This module reflects the initial scientific discussion for the approval of Ammonpas. This scientific discussion has been updated until 1 November 2001. For information on changes after this date please refer to module 8B. 1. Introduction Ammonaps, sodium phenylbutyrate (PB), is a new active substance. It is indicated as adjunctive therapy in the chronic management of urea cycle disorders, involving deficiencies of carbamylphosphate synthetase, ornithine transcarbamylase, or argininosuccinate synthetase. It is indicated in all patients with neonatal-onset presentation (complete enzyme deficiencies, presenting within the first 28 days of life). It is also indicated in patients with late-onset disease (partial enzyme deficiencies, presenting after the first month of life) who have a history of hyperammonaemic encephalopathy. The dossier submitted in support of the application comprises data generated by the applicant: all chemical/pharmaceutical data, the two mutagenicity studies for Part III, and for Part IV, the bioequivalence study and a review of the US IND/NDA programme. Additional information was available from published literature. Urea cycle disorders (UCD) are inherited deficiencies of one of the enzymes involved in the urea cycle, by which ammonium is converted to urea. Ammonium is highly toxic to nerve cells and hyperammonaemia may result in metabolic derangement, leading to anorexia, lethargy, confusion, coma, brain damage, and death. The most severe forms of UCDs occur early in life (complete enzyme deficiencies). The classic neonatal presentation of all the UCD (with the exception of arginase deficiency) is quite uniform and includes, after a short symptom-free interval of one to five days, poor feeding, vomiting, lethargy, muscular hypotonia, hyperventilation, irritability and convulsions.
    [Show full text]
  • Valturna Label
    HIGHLIGHTS OF PRESCRIBING INFORMATION -------------------------WARNINGS AND PRECAUTIONS----------------­ These highlights do not include all the information needed to use • Avoid fetal or neonatal exposure. (5.1) Valturna safely and effectively. See full prescribing information for • Head and neck angioedema: Discontinue Valturna and monitor until Valturna. signs and symptoms resolve. (5.2) • Hypotension in volume- or salt-depleted Patients: Correct imbalances Valturna (aliskiren and valsartan, USP) Tablets before initiating therapy with Valturna. (5.3) Initial U.S. Approval: 2009 • Patients with renal impairment: Decreases in renal function may be anticipated in susceptible individuals. (5.4) WARNING: AVOID USE IN PREGNANCY • Patients with hepatic impairment: Slower clearance may occur. (5.5) See full prescribing information for complete boxed warning. • Hyperkalemia: Consider periodic determinations of serum electrolytes to When pregnancy is detected, discontinue Valturna as soon as possible. detect possible electrolyte imbalances, particularly in patients at risk. When used in pregnancy during the second and third trimester, drugs (5.7) that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. (5.1) --------------------------------ADVERSE REACTIONS----------------------- The most common adverse events (incidence ≥1.5% and more common than ---------------------------INDICATIONS AND USAGE----------------------- with placebo) are: fatigue and nasopharyngitis. (6.1) Valturna is a combination of aliskiren, a direct renin inhibitor, and valsartan, an angiotensin II receptor blocker (ARB), indicated for the treatment of To report SUSPECTED ADVERSE REACTIONS, contact Novartis hypertension: Pharmaceuticals Corporation at 1-888-669-6682 or FDA at • In patients not adequately controlled with monotherapy. (1) 1-800-FDA-1088 or www.fda.gov/medwatch • May be substituted for titrated components.
    [Show full text]
  • An Approach to the Patient with a Dry Mouth
    MedicineToday 2014; 15(4): 30-37 PEER REVIEWED FEATURE 2 CPD POINTS An approach to the patient with a dry mouth Key points • The subjective complaint of ELHAM AFLAKI MD; TAHEREH ERFANI MD; NICHOLAS MANOLIOS MB BS(Hons), PhD, MD, FRACP, FRCPA; xerostomia needs to be MARK SCHIFTER FFD, RCSI(Oral Med), FRACDS(Oral Med) differentiated from true salivary hypofunction. Dry mouth is a common and disabling problem. After exclusion of treatable • Salivary hypofunction can significantly reduce quality causes, treatment is symptomatic to prevent the consequences of salivary of life through its adverse hypofunction, such as tooth decay and infection of the oral mucosa. effects on taste, mastication, swallowing, cleansing of the erostomia, or the subjective feeling of neuropathic-induced orofacial dysaesthesia) mouth, killing of microbes a dry mouth, is a common complaint. and psychological and psychiatric disorders, and speech. It is often a consequence of salivary such as anxiety and depression. • Salivary hypofunction is a hypofunction (hyposalivation), in substantive risk factor for X which there is objective evidence of reduced NORMAL SALIVA PRODUCTION dental caries, oral mucosal salivary output or qualitative changes in saliva. Under normal physiological conditions, the disease and infection, Typically, patients complain of oral dryness salivary glands produce 1000 to 1500 mL of particularly oral candidiasis. only when salivary secretion is reduced by more saliva daily as an ultrafiltrate from the circu- • Patients should be than half.1 As saliva has a crucial role in taste lating plasma. Therefore, simple dehydration investigated for contributory perception, mastication, swallowing, cleansing reduces saliva production. The parotid glands and underlying causes, of the mouth, killing of microbes and speech, are the major source of serous saliva (60 to 65% which include drugs and abnormalities in saliva production can signif- of total saliva volume), producing the stimu- rheumatological diseases.
    [Show full text]
  • Metabolic-Hydroxy and Carboxy Functionalization of Alkyl Moieties in Drug Molecules: Prediction of Structure Influence and Pharmacologic Activity
    molecules Review Metabolic-Hydroxy and Carboxy Functionalization of Alkyl Moieties in Drug Molecules: Prediction of Structure Influence and Pharmacologic Activity Babiker M. El-Haj 1,* and Samrein B.M. Ahmed 2 1 Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, University of Science and Technology of Fujairah, Fufairah 00971, UAE 2 College of Medicine, Sharjah Institute for Medical Research, University of Sharjah, Sharjah 00971, UAE; [email protected] * Correspondence: [email protected] Received: 6 February 2020; Accepted: 7 April 2020; Published: 22 April 2020 Abstract: Alkyl moieties—open chain or cyclic, linear, or branched—are common in drug molecules. The hydrophobicity of alkyl moieties in drug molecules is modified by metabolic hydroxy functionalization via free-radical intermediates to give primary, secondary, or tertiary alcohols depending on the class of the substrate carbon. The hydroxymethyl groups resulting from the functionalization of methyl groups are mostly oxidized further to carboxyl groups to give carboxy metabolites. As observed from the surveyed cases in this review, hydroxy functionalization leads to loss, attenuation, or retention of pharmacologic activity with respect to the parent drug. On the other hand, carboxy functionalization leads to a loss of activity with the exception of only a few cases in which activity is retained. The exceptions are those groups in which the carboxy functionalization occurs at a position distant from a well-defined primary pharmacophore. Some hydroxy metabolites, which are equiactive with their parent drugs, have been developed into ester prodrugs while carboxy metabolites, which are equiactive to their parent drugs, have been developed into drugs as per se.
    [Show full text]
  • WITHOUTUS010307409B2 (12 ) United States Patent ( 10 ) Patent No
    WITHOUTUS010307409B2 (12 ) United States Patent ( 10 ) Patent No. : US 10 , 307 ,409 B2 Chase et al. (45 ) Date of Patent: Jun . 4 , 2019 ( 54 ) MUSCARINIC COMBINATIONS AND THEIR (52 ) U . S . CI. USE FOR COMBATING CPC . .. .. A61K 31/ 4439 (2013 . 01 ) ; A61K 9 /0056 HYPOCHOLINERGIC DISORDERS OF THE (2013 . 01 ) ; A61K 9 / 7023 ( 2013 . 01 ) ; A61K CENTRAL NERVOUS SYSTEM 31 / 166 ( 2013 . 01 ) ; A61K 31 / 216 ( 2013 . 01 ) ; A61K 31 /4178 ( 2013 .01 ) ; A61K 31/ 439 (71 ) Applicant: Chase Pharmaceuticals Corporation , ( 2013 .01 ) ; A61K 31 /44 (2013 . 01 ) ; A61K Washington , DC (US ) 31/ 454 (2013 .01 ) ; A61K 31/ 4725 ( 2013 .01 ) ; A61K 31 /517 (2013 .01 ) ; A61K 45 / 06 ( 72 ) Inventors : Thomas N . Chase , Washington , DC (2013 . 01 ) (US ) ; Kathleen E . Clarence -Smith , ( 58 ) Field of Classification Search Washington , DC (US ) CPC .. A61K 31/ 167 ; A61K 31/ 216 ; A61K 31/ 439 ; A61K 31 /454 ; A61K 31 /4439 ; A61K (73 ) Assignee : Chase Pharmaceuticals Corporation , 31 /4175 ; A61K 31 /4725 Washington , DC (US ) See application file for complete search history. ( * ) Notice : Subject to any disclaimer, the term of this (56 ) References Cited patent is extended or adjusted under 35 U . S . C . 154 (b ) by 0 days . U . S . PATENT DOCUMENTS 5 ,534 ,520 A 7 / 1996 Fisher et al. ( 21) Appl . No. : 15 /260 , 996 2008 /0306103 Al 12 /2008 Fisher et al. 2011/ 0021503 A1* 1/ 2011 Chase . .. A61K 31/ 27 ( 22 ) Filed : Sep . 9 , 2016 514 / 215 2011/ 0071135 A1 * 3 / 2011 Chase . .. .. .. A61K 31/ 166 (65 ) Prior Publication Data 514 / 215 2011 /0245294 Al 10 / 2011 Paborji et al.
    [Show full text]
  • Optum Essential Health Benefits Enhanced Formulary PDL January
    PENICILLINS ketorolac tromethamineQL GENERIC mefenamic acid amoxicillin/clavulanate potassium nabumetone amoxicillin/clavulanate potassium ER naproxen January 2016 ampicillin naproxen sodium ampicillin sodium naproxen sodium CR ESSENTIAL HEALTH BENEFITS ampicillin-sulbactam naproxen sodium ER ENHANCED PREFERRED DRUG LIST nafcillin sodium naproxen DR The Optum Preferred Drug List is a guide identifying oxacillin sodium oxaprozin preferred brand-name medicines within select penicillin G potassium piroxicam therapeutic categories. The Preferred Drug List may piperacillin sodium/ tazobactam sulindac not include all drugs covered by your prescription sodium tolmetin sodium drug benefit. Generic medicines are available within many of the therapeutic categories listed, in addition piperacillin sodium/tazobactam Fenoprofen Calcium sodium to categories not listed, and should be considered Meclofenamate Sodium piperacillin/tazobactam as the first line of prescribing. Tolmetin Sodium Amoxicillin/Clavulanate Potassium LOW COST GENERIC PREFERRED For benefit coverage or restrictions please check indomethacin your benefit plan document(s). This listing is revised Augmentin meloxicam periodically as new drugs and new prescribing LOW COST GENERIC naproxen kit information becomes available. It is recommended amoxicillin that you bring this list of medications when you or a dicloxacillin sodium CARDIOVASCULAR covered family member sees a physician or other penicillin v potassium ACE-INHIBITORS healthcare provider. GENERIC QUINOLONES captopril ANTI-INFECTIVES
    [Show full text]
  • New Zealand Data Sheet
    NEW ZEALAND DATA SHEET 1. PRODUCT NAME INCRUSE ELLIPTA Umeclidinium (as bromide), 62.5 micrograms, powder for inhalation 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each delivered dose (the dose leaving the mouthpiece of the inhaler) contains 55 micrograms umeclidinium (equivalent to 65 micrograms of umeclidinium bromide). This corresponds to a pre-dispensed dose of 62.5 micrograms of umeclidinium (equivalent to 74.2 micrograms umeclidinium bromide). Excipient with known effect: Each delivered dose contains approximately 12.5 mg of lactose (as monohydrate). For the full list of excipients, see section 6.1 List of excipients. 3. PHARMACEUTICAL FORM Powder for Inhalation White powder in a grey inhaler (Ellipta) with a light green mouthpiece cover and a dose counter. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Incruse Ellipta is indicated as a long-term once daily maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD). 4.2 Dose and method of administration Dose Adults Incruse Ellipta (umeclidinium 62.5 micrograms) should be taken as one inhalation once daily by the orally inhaled route. Incruse Ellipta should be taken at the same time every day. Do not use Incruse Ellipta more than once every 24 hours. Special populations Elderly population No dosage adjustment is required in patients over 65 years (see 5.2 Pharmacokinetics properties– Special patient populations). 1 Renal impairment No dosage adjustment is required in patients with renal impairment (see 5.2 Pharmacokinetics properties – Special patient populations). Hepatic impairment No dosage adjustment is required in patients with mild or moderate hepatic impairment. Incruse Ellipta has not been studied in patients with severe hepatic impairment (see 5.2 Pharmacokinetics properties– Special patient populations).
    [Show full text]
  • Eslicarbazepine Acetate Longer Procedure No
    European Medicines Agency London, 19 February 2009 Doc. Ref.: EMEA/135697/2009 CHMP ASSESSMENT REPORT FOR authorised Exalief International Nonproprietary Name: eslicarbazepine acetate longer Procedure No. EMEA/H/C/000987 no Assessment Report as adopted by the CHMP with all information of a commercially confidential nature deleted. product Medicinal 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 84 16 E-mail: [email protected] http://www.emea.europa.eu TABLE OF CONTENTS 1. BACKGROUND INFORMATION ON THE PROCEDURE........................................... 3 1.1. Submission of the dossier ...................................................................................................... 3 1.2. Steps taken for the assessment of the product..................................................................... 3 2. SCIENTIFIC DISCUSSION................................................................................................. 4 2.1. Introduction............................................................................................................................ 4 2.2. Quality aspects ....................................................................................................................... 5 2.3. Non-clinical aspects................................................................................................................ 8 2.4. Clinical aspects....................................................................................................................
    [Show full text]
  • Potentially Harmful Drugs in the Elderly: Beers List
    −This Clinical Resource gives subscribers additional insight related to the Recommendations published in− March 2019 ~ Resource #350301 Potentially Harmful Drugs in the Elderly: Beers List In 1991, Dr. Mark Beers and colleagues published a methods paper describing the development of a consensus list of medicines considered to be inappropriate for long-term care facility residents.12 The “Beers list” is now in its sixth permutation.1 It is intended for use by clinicians in outpatient as well as inpatient settings (but not hospice or palliative care) to improve the care of patients 65 years of age and older.1 It includes medications that should generally be avoided in all elderly, used with caution, or used with caution or avoided in certain elderly.1 There is also a list of potentially harmful drug-drug interactions in seniors, as well as a list of medications that may need to be avoided or have their dosage reduced based on renal function.1 This information is not comprehensive; medications and interactions were chosen for inclusion based on potential harm in relation to benefit in the elderly, and availability of alternatives with a more favorable risk/benefit ratio.1 The criteria no longer address drugs to avoid in patients with seizures or insomnia because these concerns are not unique to the elderly.1 Another notable deletion is H2 blockers as a concern in dementia; evidence of cognitive impairment is weak, and long-term PPIs pose risks.1 Glimepiride has been added as a drug to avoid. Some drugs have been added with cautions (dextromethorphan/quinidine, trimethoprim/sulfamethoxazole), and some have had cautions added (rivaroxaban, tramadol, SNRIs).
    [Show full text]
  • Prediction of Premature Termination Codon Suppressing Compounds for Treatment of Duchenne Muscular Dystrophy Using Machine Learning
    Prediction of Premature Termination Codon Suppressing Compounds for Treatment of Duchenne Muscular Dystrophy using Machine Learning Kate Wang et al. Supplemental Table S1. Drugs selected by Pharmacophore-based, ML-based and DL- based search in the FDA-approved drugs database Pharmacophore WEKA TF 1-Palmitoyl-2-oleoyl-sn-glycero-3- 5-O-phosphono-alpha-D- (phospho-rac-(1-glycerol)) ribofuranosyl diphosphate Acarbose Amikacin Acetylcarnitine Acetarsol Arbutamine Acetylcholine Adenosine Aldehydo-N-Acetyl-D- Benserazide Acyclovir Glucosamine Bisoprolol Adefovir dipivoxil Alendronic acid Brivudine Alfentanil Alginic acid Cefamandole Alitretinoin alpha-Arbutin Cefdinir Azithromycin Amikacin Cefixime Balsalazide Amiloride Cefonicid Bethanechol Arbutin Ceforanide Bicalutamide Ascorbic acid calcium salt Cefotetan Calcium glubionate Auranofin Ceftibuten Cangrelor Azacitidine Ceftolozane Capecitabine Benserazide Cerivastatin Carbamoylcholine Besifloxacin Chlortetracycline Carisoprodol beta-L-fructofuranose Cilastatin Chlorobutanol Bictegravir Citicoline Cidofovir Bismuth subgallate Cladribine Clodronic acid Bleomycin Clarithromycin Colistimethate Bortezomib Clindamycin Cyclandelate Bromotheophylline Clofarabine Dexpanthenol Calcium threonate Cromoglicic acid Edoxudine Capecitabine Demeclocycline Elbasvir Capreomycin Diaminopropanol tetraacetic acid Erdosteine Carbidopa Diazolidinylurea Ethchlorvynol Carbocisteine Dibekacin Ethinamate Carboplatin Dinoprostone Famotidine Cefotetan Dipyridamole Fidaxomicin Chlormerodrin Doripenem Flavin adenine dinucleotide
    [Show full text]